全文获取类型
收费全文 | 501篇 |
免费 | 50篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 9篇 |
妇产科学 | 5篇 |
基础医学 | 76篇 |
口腔科学 | 24篇 |
临床医学 | 56篇 |
内科学 | 112篇 |
皮肤病学 | 22篇 |
神经病学 | 35篇 |
特种医学 | 11篇 |
外科学 | 34篇 |
综合类 | 1篇 |
预防医学 | 22篇 |
眼科学 | 7篇 |
药学 | 76篇 |
中国医学 | 1篇 |
肿瘤学 | 56篇 |
出版年
2024年 | 1篇 |
2023年 | 15篇 |
2022年 | 45篇 |
2021年 | 48篇 |
2020年 | 21篇 |
2019年 | 39篇 |
2018年 | 34篇 |
2017年 | 20篇 |
2016年 | 23篇 |
2015年 | 22篇 |
2014年 | 28篇 |
2013年 | 25篇 |
2012年 | 54篇 |
2011年 | 41篇 |
2010年 | 19篇 |
2009年 | 16篇 |
2008年 | 11篇 |
2007年 | 18篇 |
2006年 | 13篇 |
2005年 | 14篇 |
2004年 | 12篇 |
2003年 | 10篇 |
2002年 | 16篇 |
2001年 | 4篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1989年 | 1篇 |
排序方式: 共有553条查询结果,搜索用时 323 毫秒
71.
Emad A. Rakha Islam M. Miligy Cecily M. Quinn Elena Provenzano Abeer M. Shaaban Caterina Marchi Michael S. Toss Grace Gallagy Ciara Murray Janice Walshe Ayaka Katayama Karim Eldib Nahla Badr Bruce Tanchel Rebecca Millican-Slater Colin Purdie Dave Purnell Sarah E. Pinder Ian O. Ellis Andrew H. S. Lee 《British journal of cancer》2021,124(11):1836
Background The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number <4.0 signals/cell were re-classified as HER2 negative. This study aims to examine the response of Group 2 tumours to neoadjuvant chemotherapy (NACT).Methods 749 BC cases were identified from 11 institutions. The association between HER2 groups and pathological complete response (pCR) was assessed.Results 54% of immunohistochemistry HER2 positive (score 3+) BCs showed pCR, compared to 19% of immunohistochemistry 2+ FISH amplified cases. 27% of Group 2 treated with HER2 targeted therapy achieved pCR, compared to 19 and 11% in the combined Groups 1 + 3 and Groups 4 + 5, respectively. No difference in pCR rates was identified between Group 2 and Group 1 or combined Groups 1 + 3. However, Group 2 response rate was higher than Groups 4 + 5 (p = 0.017).Conclusion No difference in pCR was detected in tumours with a HER2/CEP17 ratio ≥2.0 and a HER2 score 2+ by IHC when stratified by HER2 gene copy number. Our data suggest that ASCO/CAP HER2 Group 2 carcinomas should be evaluated further with respect to eligibility for HER2 targeted therapy.Subject terms: Breast cancer, Breast cancer 相似文献
72.
Kumiko Kito Junko Ishihara Ayaka Kotemori Ling Zha Rong Liu Norie Sawada Motoki Iwasaki Tomotaka Sobue Shoichiro Tsugane 《Nutrients》2020,12(11)
Acrylamide is a probable carcinogen in humans. Few studies have assessed dietary acrylamide intake and the risk of pancreatic cancer; however, these studies are based on Western populations. Our purpose was to investigate the association of dietary acrylamide intake with the risk of pancreatic cancer utilizing data from the Japan Public Health Center-based Prospective Study. We evaluated the data of 89,729 participants aged 45–74 years, who replied to a questionnaire on past medical history and lifestyle habits from 1995–1998. Dietary acrylamide intake was estimated utilizing a validated food frequency questionnaire. We calculated the hazard ratios and 95% confidence intervals by using Cox proportional-hazards regression models. The average follow-up was 15.2 years, and 576 cases of pancreatic cancer were diagnosed. In the multivariate-adjusted model, an association between dietary acrylamide intake and pancreatic cancer risk was not demonstrated (hazard ratio for the highest vs. lowest quartile = 0.83, 95% confidence interval: 0.65–1.05, p for trend = 0.07). Furthermore, in the analyses stratified by sex, smoking status, coffee consumption, green tea consumption, alcohol consumption, and body mass index, no significant association was detected. Dietary acrylamide intake was not associated with the pancreatic cancer risk in Japanese individuals. 相似文献
73.
Manaka Muneishi Ayaka Nakamura Katsumi Tachibana Junko Suemitsu Shinji Hasebe Kazuto Takeuchi Yoshihiro Yakushijin 《International journal of clinical oncology / Japan Society of Clinical Oncology》2018,23(2):375-381
Background
Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL), with indolent progression. Several treatment options are selected, based not only on disease status, quality of life (QOL), and age of patient, but also on recent increasing medical costs. We retrospectively analysed the first-line treatment of FL with regard to treatment outcomes and medical economics, and discuss the appropriate strategies for FL.Methods
Data on a total of 69 newly-diagnosed patients with FL was retrospectively collected from 2001 to 2015.Results
The median age of the patients was 60 years and the median follow-up was 58 months. A total of 25 cases with FL were treated with R monotherapy, and 28 cases were treated with R-CHOP as first-line treatment. The factors affecting the decision of physicians to use R or R-CHOP treatment were serum level of lactate dehydrogenase (LDH) and disease stage. The first-line treatment-associated survival did not show any statistical differences between R and R-CHOP. The average hospitalization and average of all medical costs during the first-line treatment were 4.1 days (R) versus 55.7 days (R-CHOP), and JPY 1,707,693 (USD 15,324) (R) versus JPY 2,136,117 (USD 19,170) (R-CHOP), respectively.Conclusion
R monotherapy for patients whose diseases show low tumor burden and who are not candidates for local treatment has benefits as a first-line treatment compared to R-CHOP, based on the patients’ QOL and medical economics.74.
Coffee drinking and colorectal cancer and its subsites: A pooled analysis of 8 cohort studies in Japan
下载免费PDF全文
![点击此处可从《International journal of cancer. Journal international du cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Tetsuya Mizoue Norie Sawada Ayaka Kotemori Keitaro Matsuo Isao Oze Hidemi Ito Mariko Naito Tomio Nakayama Yuri Kitamura Akiko Tamakoshi Ichiro Tsuji Yumi Sugawara Manami Inoue Chisato Nagata Atsuko Sadakane Keitaro Tanaka Shoichiro Tsugane Taichi Shimazu for the Research Group for the Development Evaluation of Cancer Prevention Strategies in Japan 《International journal of cancer. Journal international du cancer》2018,143(2):307-316
Coffee is a rich source of bioactive compounds that have potential anticarcinogenic effects. However, it remains unclear whether coffee drinking is associated with colorectal cancer. Also, despite different etiological factors involved in gut physiology, few studies have investigated this association by anatomical site of the lesion. To address these issues, this study examined the association between coffee drinking and colorectal cancer in a pooled analysis from 8 cohort studies conducted in Japan. Among 320,322 participants followed up for 4,503,274 person‐years, 6,711 incident colorectal cancer cases were identified. Study‐specific hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models and then pooled using the random effects model. Coffee drinking was not materially associated with colorectal cancer risk in men or women (pooled HR 0.92, 95% CI 0.82–1.03 in men and pooled HR 0.90, 95% CI 0.76–1.07 in women). Analysis by subsite showed a lower risk of colon cancer among female drinkers of ≥3 cups coffee/day (pooled HR 0.80, 95% CI 0.64–0.99). There was no such association in men. Coffee drinking was not associated with risk of rectal cancer in men or women. Results were virtually the same among never smokers except for an increased risk of rectal cancer associated with frequent coffee consumption. Coffee drinking may be associated with lower risk of colon cancer in Japanese women. 相似文献
75.
76.
Ayaka Shimo Koichiro Tsugawa Seiko Tsuchiya Reiko Yoshie Kyoko Tsuchiya Tomoko Uejima Yasuyuki Kojima Arata Shimo Ryosuke Hayami Toru Nishikawa Yukari Yabuki Hisanori Kawamoto Akihiko Sudo Mamoru Fukuda Yoshihide Kanemaki Ichiro Maeda 《Breast cancer (Tokyo, Japan)》2016,23(6):851-860
Background
Nipple-sparing mastectomy (NSM) is an advantageous treatment option, providing a complete cure and good cosmetic results. We tested whether NSM is a surgically and oncologically safe technique.Methods
We evaluated the oncological outcome of 425 breasts in 413 patients who underwent NSM between January 2000 and March 2013. We retrospectively reviewed patient data and analyzed all patient characteristics as potential risk factors of recurrence at the nipple–areola complex (NAC). To confirm the oncological safety of NSM, we compared outcomes of NSM and conventional total mastectomy.Results
The median follow-up time after surgery was 46.8 months (range 6–158 months). Nipple necrosis was observed in 6 cases (1.4 %). The cumulative local recurrence rate after NSM was 5.8 % (25/425 cases), similar to that of conventional total mastectomy in the same period (5.6 %, 49/878 cases). Furthermore, the cumulative local recurrence rate at the NAC was 2.3 % (10 cases). HER2-enriched tumors and young age (<40 years) were significant risk factors for recurrence at the NAC. In patients with recurrence, the site of recurrence was easily excised, and good cosmetic results were achieved in breast reconstruction cases.Conclusion
NSM is safe with a low complication rate. No significant difference was observed in cumulative local recurrence rate, cumulative distant disease recurrence rate, and overall survival between patients who underwent NSM or conventional total mastectomy, confirming that NSM was surgically and oncologically safe.77.
Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis
下载免费PDF全文
![点击此处可从《Cancer science》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Koichi Goto Masahiro Endo Masahiko Kusumoto Nobuyuki Yamamoto Yuichiro Ohe Ayaka Shimizu Masahiro Fukuoka 《Cancer science》2016,107(12):1837-1842
Potentially life‐threatening, serious hemoptysis is an adverse event associated with bevacizumab in non‐squamous non‐small‐cell lung cancer (NSCLC) trials. Suggested risk factors include central tumor location and cavitation; however, the profile of hemoptysis occurrence in clinical practice is still unclear. A nested case‐control study was conducted to assess the onset profile and risk factors for hemoptysis in bevacizumab‐treated patients in a real‐world setting in Japan. After bevacizumab was approved for NSCLC, physicians registered all NSCLC patients scheduled for bevacizumab therapy, from November 2009 to August 2011. Patients developing grade 2 hemoptysis requiring an injectable hemostatic agent or grade ≥3 hemoptysis were selected as case subjects, matched with four control subjects each. Case report forms were collected after an observation period of 24 weeks. Radiologists assessed blinded thoracic images. Risk factors for hemoptysis were assessed by univariate and stepwise multivariate analysis. Of 6774 patients registered, 23 (0.3%) experienced grade ≥2 drug‐related hemoptysis. A total of 104 patients (21 cases, 83 controls) were analyzed by central reviewers for risk factors of hemoptysis occurrence. In the univariate analysis seven factors were associated with hemoptysis. In the step‐wise multivariate analysis, prior thoracic radiotherapy (P = 0.1844), presence of tumor exposure in the central airway (P = 0.0256) and concomitant radiotherapy (P = 0.1169) were identified as risk factors for hemoptysis. While the incidence of hemoptysis was low in the real‐world setting in Japan, the three risk factors identified, prior thoracic radiotherapy, presence of tumor exposure in the central airway and concomitant radiotherapy, should be considered when selecting patients for bevacizumab treatment. Although technically classed as a clinical trial, a nested case‐control study was a non‐interventional surveillance study analyzing all NSCLC patients receiving bevacizumab in Japan, therefore it was not registered as a phase II/III clinical trial would be. 相似文献
78.
Different induction of LPA receptors by chemical liver carcinogens regulates cellular functions of liver epithelial WB‐F344 cells
下载免费PDF全文
![点击此处可从《Molecular carcinogenesis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
79.
Muratsugu M Yazawa A Fujiwara S Nishida S Fukui T 《Biological & pharmaceutical bulletin》2008,31(3):507-510
Biotin-binding IgG (B-IgG) in human sera was quantified using previously developed F(ab')(2)anti-human IgG-coated multiwell microplates (Muratsugu M. et al., 2003, Biol. Pharm. Bull., 26, 1605--1608). The levels of B-IgG in sera, however, were higher than those we predicted. In this study, we modified the assay using F(ab')2anti-human IgG-coated multiwell microplates and successfully quantified the levels of B-IgG in sera. The cause of the unpredicted results was discussed in the text. In addition, the levels of biotin-binding IgA (B-IgA) and IgM (B-IgM) in sera could be measured using F(ab')2anti-human IgA- or IgM-coated multiwell microplates. We quantified B-IgG, B-IgA, and B-IgM in sera from healthy specimens and patients with bronchial asthma, atopic dermatitis, epilepsy, and juvenile rheumatoid arthritis. 相似文献
80.
Fujimura Yoshinori Yoshimoto Takanori Fujino Konatsu Nezu Ayaka Marugame Yuki Bae Jaehoon Kumazoe Motofumi Tachibana Hirofumi 《Journal of natural medicines》2023,77(2):363-369
Journal of Natural Medicines - Many patients with allergies have anxiety about taking anti-allergic medicines due to their side effects and increased medical expenses. Thus, developing functional... 相似文献